BioStock: BioInvent delivers in 2021; more to come in 2022

Swedish biotech company BioInvent recently published its year-end report, which reflects a year of significant progress for the company. After raising capital in February, the company was able to expand its clinical pipeline from two to four programmes, with yet another approved in early 2022. In December, the company presented promising phase I data from its leading candidate BI-1206, raising expectations on an interesting 2022. BioStock reached out to CEO Martin Welschof for a comment.

Read the interview with BioInvent's CEO Martin Welschof at biostock.se:

https://www.biostock.se/en/2022/02/bioinvent-delivers-in-2021-more-to-come-in-2022/

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se/en/